中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2015年
13期
2013-2015,2016
,共4页
钱发英%吴海燕%童欣%钟斌
錢髮英%吳海燕%童訢%鐘斌
전발영%오해연%동흔%종빈
支原体肺炎%阿奇霉素%红霉素%序贯疗法
支原體肺炎%阿奇黴素%紅黴素%序貫療法
지원체폐염%아기매소%홍매소%서관요법
Mycoplasma pneumonia%Azithromycin%Erythromycin%Sequential therapy
目的:观察阿奇霉素序贯疗法治疗小儿支原体肺炎的临床疗效及安全性。方法选取支原体肺炎患儿112例,按随机数字表法分为观察组和对照组,各56例,观察组予以阿奇霉素序贯疗法治疗,对照组予乳糖酸红霉素抗感染治疗,比较两组患儿治疗后的临床疗效、临床症状体征消失时间及药物不良反应发生情况。结果观察组治疗总有效率为96.43%,明显高于对照组患儿的80.36%,差异有统计学意义(χ2=7.04,P <0.05)。观察组患儿发热、咳嗽、肺部啰音消失时间分别为(3.74±1.58)d、(3.24±0.47)d、(5.58±2.23)d,均明显短于对照组患儿的(4.68±1.71)d、(4.64±0.97)d、(7.82±2.70)d(t =4.27、4.68、4.59,均P <0.05)。观察组患儿胃肠道反应、局部疼痛、皮疹、ALT 升高发生率明显低于对照组,差异均有统计学意义(χ2=4.26、7.04、7.03、5.23,均 P <0.05)。结论阿奇霉素序贯疗法用于治疗小儿支原体肺炎具有临床疗效好、起效快、安全性高的优点。
目的:觀察阿奇黴素序貫療法治療小兒支原體肺炎的臨床療效及安全性。方法選取支原體肺炎患兒112例,按隨機數字錶法分為觀察組和對照組,各56例,觀察組予以阿奇黴素序貫療法治療,對照組予乳糖痠紅黴素抗感染治療,比較兩組患兒治療後的臨床療效、臨床癥狀體徵消失時間及藥物不良反應髮生情況。結果觀察組治療總有效率為96.43%,明顯高于對照組患兒的80.36%,差異有統計學意義(χ2=7.04,P <0.05)。觀察組患兒髮熱、咳嗽、肺部啰音消失時間分彆為(3.74±1.58)d、(3.24±0.47)d、(5.58±2.23)d,均明顯短于對照組患兒的(4.68±1.71)d、(4.64±0.97)d、(7.82±2.70)d(t =4.27、4.68、4.59,均P <0.05)。觀察組患兒胃腸道反應、跼部疼痛、皮疹、ALT 升高髮生率明顯低于對照組,差異均有統計學意義(χ2=4.26、7.04、7.03、5.23,均 P <0.05)。結論阿奇黴素序貫療法用于治療小兒支原體肺炎具有臨床療效好、起效快、安全性高的優點。
목적:관찰아기매소서관요법치료소인지원체폐염적림상료효급안전성。방법선취지원체폐염환인112례,안수궤수자표법분위관찰조화대조조,각56례,관찰조여이아기매소서관요법치료,대조조여유당산홍매소항감염치료,비교량조환인치료후적림상료효、림상증상체정소실시간급약물불량반응발생정황。결과관찰조치료총유효솔위96.43%,명현고우대조조환인적80.36%,차이유통계학의의(χ2=7.04,P <0.05)。관찰조환인발열、해수、폐부라음소실시간분별위(3.74±1.58)d、(3.24±0.47)d、(5.58±2.23)d,균명현단우대조조환인적(4.68±1.71)d、(4.64±0.97)d、(7.82±2.70)d(t =4.27、4.68、4.59,균P <0.05)。관찰조환인위장도반응、국부동통、피진、ALT 승고발생솔명현저우대조조,차이균유통계학의의(χ2=4.26、7.04、7.03、5.23,균 P <0.05)。결론아기매소서관요법용우치료소인지원체폐염구유림상료효호、기효쾌、안전성고적우점。
Objective To observe the clinical efficacy and safety of Azithromycin Sequential Therapy in the treatment of mycoplasma pneumonia for children.Methods 112 children with mycoplasma pneumonia were randomly divided into observation group and control group,each 56 cases.The observation group was treated with Azithromycin Sequential Therapy in the treatment,while the control group was treated with erythromycin lactobionate anti infection treatment.The clinical efficacy was compared between two groups after treatment,the clinical symptoms disappeared time and drug adverse reaction occurred the situation.Results The total effective rate of the observation group was 96.43%,which was significantly higher than 80.36% of the control group,the difference was statistically significant (χ2 =7.04,P <0.05).The fever,cough,pulmonary rales disappearance time of the observation group were (3.74 ± 1.58)d,(3.24 ±0.47)d,(5.58 ±2.23)d,which were significantly shorter than (4.68 ±1.71 )d,(4.64 ± 0.97)d,(7.82 ±2.70)d of the control group(t =4.27,4.68,4.59,all P <0.05).The gastrointestinal reactions, local pain,rash,the elevation of ALT of the observation group were significantly lower than the control group,the difference was statistically significant (χ2 =4.26,7.04,7.03,5.23,all P <0.05 ).Conclusion Azithromycin Sequential Therapy for the treatment of mycoplasma pneumonia in children has the advantages of good clinical effica-cy,fast effect,high safety.